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Abstract
Background: Estrogen is a known growth promoter for estrogen receptor (ER)-positive breast cancer cells. Paradoxically, in breast
cancer cells that have been chronically deprived of estrogen stimulation, re-introduction of the hormone can induce apoptosis.
Methodology/Principal Findings: Here, we sought to identify signaling networks that are triggered by estradiol (E2) in
isogenic MCF-7 breast cancer cells that undergo apoptosis (MCF-7:5C) versus cells that proliferate upon exposure to E2
(MCF-7). The nuclear receptor co-activator AIB1 (Amplified in Breast Cancer-1) is known to be rate-limiting for E2-induced
cell survival responses in MCF-7 cells and was found here to also be required for the induction of apoptosis by E2 in the
MCF-7:5C cells. Proteins that interact with AIB1 as well as complexes that contain tyrosine phosphorylated proteins were
isolated by immunoprecipitation and identified by mass spectrometry (MS) at baseline and after a brief exposure to E2 for
two hours. Bioinformatic network analyses of the identified protein interactions were then used to analyze E2 signaling
pathways that trigger apoptosis versus survival. Comparison of MS data with a computationally-predicted AIB1 interaction
network showed that 26 proteins identified in this study are within this network, and are involved in signal transduction,
transcription, cell cycle regulation and protein degradation.
Conclusions: G-protein-coupled receptors, PI3 kinase, Wnt and Notch signaling pathways were most strongly associated
with E2-induced proliferation or apoptosis and are integrated here into a global AIB1 signaling network that controls
qualitatively distinct responses to estrogen.
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Introduction
Estrogen induces proliferation of estrogen receptor (ER)-positive
breast cancer cells [1]. This response is consistent with the finding
that antihormone therapies, such as tamoxifen or aromatase
inhibitors, can enhance survivorship and reduce recurrence in
patients with ER-positive breast cancers [2,3]. However, the
majority of tumors eventually become unresponsive to antihor-
mone treatments [4,5] and molecular mechanisms and markers of
antihormone resistance have been described [6,7]. Once patients
have failed on antihormone therapy, one treatment option has
been the use of pharmacologic doses of estrogens [8,9] based on
well-established findings that some breast cancers shrink during
high dose estrogen treatment [10,11,12]. This phenomenon has
also been observed in laboratory models of ER-positive breast
cancer with acquired anti-hormone resistance that regress and
undergo apoptosis in the presence of physiologic concentrations of
estrogen [13,14] and was reviewed recently for its potential clinical
implications [15].
Estrogen exerts diverse effects including genomic and non-
genomic effects through multiple signaling pathways, that are
significantly altered in anti-hormone resistant ER positive breast
cancer cells. In antihormone resistant cells, for example, there is a
general increase in EGFR and IGFR tyrosine kinase signaling
[16,17], accompanied by increased ligand-independent phosphor-
ylation of ER [18] and nuclear receptor co-activators such as
AIB1/SRC3 (Amplified in Breast Cancer 1/Steroid Receptor Co-
activator3) [19]. Overexpression and activation of AIB1 is
associated with endocrine resistance in human breast cancer
[20,21,22] and has been shown to be rate-limiting for estrogen-
induced growth of breast cancer cells [23,24]. Beyond its role in
these effects of estrogen, AIB1 was also shown to be rate-limiting
for the growth of estrogen-insensitive breast cancer cells [25] as
well as prostate cancer [26], pancreatic cancer [27] and
lymphoma cells [28]. Furthermore, in AIB1 knockout mice,
responses to hormones [29] as well as growth factor signaling [30]
are blunted whereas overexpression of an AIB1 transgene leads to
increased estrogen and growth factor responses resulting in
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large body of data support a crucial role for AIB1 in estrogen and
growth factor signaling (reviewed in Refs [34,35]) and provides the
rationale for the experimental paradigm used here.
To identify pathways that initiate estrogen-induced apoptosis
versus growth, we used a combined proteomics and systems
biology approach to elucidate triggering events and associated
signaling pathways. We focused on changes of AIB1 interacting
proteins, because of its central role in estrogen control of
phenotypic behavior of breast cancer cells outlined above. AIB1
also coactivates IGF1R, EGFR and HER2 through modulation of
tyrosine phosphorylation of these transmembrane receptors and
phosphorylation of their subsequent signaling intermediaries
[27,30,33,34]. Thus, to complement the analysis of direct AIB1
interacting proteins, we also monitored changes of phosphotyr-
osine (pY)-containing protein complexes, that are most likely
regulated by growth factor signaling, as a means of discovering
global intersecting pathways. As a model system, we used MCF-7
cells that proliferate in response to E2 [1], but also respond to EGF
and heregulin [36] and have high levels of AIB1 protein due to
gene amplification [37]. Wild-type MCF-7 cells were compared
with MCF-7:5C cells that had been isolated under estrogen-free
growth conditions [38,39]. MCF-7:5C cells were derived following
long-term culture of MCF-7 cells in phenol red-free media. MCF-
7:5C cells are ER-positive and undergo apoptosis after exposure to
physiological concentrations of E2. In contrast, wild-type parental
MCF-7 cells proliferate in the presence of the same concentration
range of E2 [38,39]. The MCF-7:5C cells represent many of the
characteristics of Phase II SERM resistant cells [40]. A parallel
analysis after estrogen stimulation of these isogenic breast cancer
cell lines served as a basis for the comparisons of signaling
responses.
Here, we show that RNAi-mediated depletion of AIB1 reduces
E2-induced growth of MCF-7 cells, and reverses the estrogen-
induced apoptosis in MCF-7:5C cells. AIB1-interacting and pY-
containing protein complexes were immunoprecipitated from
short-term E2-treated cells, and the complexed proteins were
identified by mass spectrometry (MS) analysis (Fig. 1A). From a
comparison of the data sets obtained with MCF-7 versus MCF-
7:5C cells treated with or without E2, and from a computationally-
derived global AIB1-interacting network prediction, we identified
pathways that participate in the differential response to E2 in these
breast cancer cells. We found that a limited number of major
cellular signaling pathways i.e. GPCR, PI3 kinase, Wnt, Notch
Figure 1. Phenotypic impact of AIB1 depletion on estradiol (E2) growth response in MCF-7 or MCF-7:5C cells. (A) The experimental
paradigm. The differential responses to estradiol (E2) treatment of MCF-7 (cell growth) and long-term estrogen deprived MCF-7:5C cells (apoptosis)
are indicated. Proteomics profiles of the two cell lines at baseline and after a brief (2 h) E2 treatment were generated using immunoprecipitations (IP).
Proteins interacting with AIB1 or phosphotyrosine containing protein complexes were isolated by IP followed by mass spectrometry. Data were then
subjected to an integrated bioinformatics analysis of signaling pathways and protein networks. (B,C) Reversal of E2-dependent effects on MCF-7 and
MCF-7:5C after depletion of endogenous AIB1 protein using two different lentiviral shRNAs. MCF-7 or MCF-7:5C cells were infected with lentiviral
particles expressing control or AIB1-targeting shRNAs. (B) RNAi-mediated knockdown was assayed by Western blot analysis for AIB1 relative to an
actin loading control. (C) Cell growth was assayed 6 days after plating without or with E2. The E2 effect is shown relative to the respective untreated
controls (mean 6S.E.M.). Closed circles: control shRNA; Open circles (red): AIB1 shRNA. #,p ,0.05 E2 treatment effect vs. no treatment in control
shRNA cells; *, p,0.05 E2 treatment effect in control shRNA cells vs. E2 treatment in AIB1 depleted cells. Representative data from one of at least
three independent experiments are shown.
doi:10.1371/journal.pone.0020410.g001
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estrogen induced proliferative or apoptotic responses. This
information will be useful for determining appropriate targets to
induce apoptosis in endocrine resistant human breast cancer.
Results and Discussion
Impact of AIB1 depletion on E2-induced growth effects
in MCF-7 and MCF-7:5C cells
To determine the role of AIB1 in the E2-induced, distinct
growth phenotypes of MCF-7:5C and wild-type MCF-7 cells, both
cell lines were infected with lentiviral vectors that express control
or two distinct AIB1-targeted shRNAs, and selected in puromycin
for stable integrants. Both MCF-7 and MCF-7:5C cells were
depleted of AIB1 protein, compared to uninfected and control
shRNA infected cells with either of the shRNAs (Fig. 1B).
Treatment with E2 significantly induced growth of control
shRNA-infected MCF-7 cells and reduced the growth of MCF-
7:5C cells (Fig. 1C, black symbols). In contrast to this, in AIB1-
depleted, wild-type MCF-7 cells, E2 did not stimulate growth
significantly above baseline and in AIB1 depleted MCF-7:5C, E2
lost its apoptosis-inducing effect (Fig. 1C, red symbols). These data
suggest that AIB1 is a significant control hub of the E2-controlled
growth phenotype in these ER-positive breast cancer cells.
Global analysis of AIB1- and phosphotyrosine-complexed
proteins
Because AIB1 is rate-limiting for the E2-induced changes in the
growth phenotype of MCF-7 and MCF-7:5C cells, we performed
AIB1-specific immunoprecipitations of lysates from untreated and
E2-treated (2 hrs) MCF-7 and MCF-7:5C cells to fractionate the
respective proteome. Immunoprecipitation of phosphotyrosine-
containing protein complexes was also performed to complement
the AIB1-specific proteome fractionation (Fig. 1A). The immuno-
precipitates were released from the beads, separated by denaturing
gel electrophoreses (SDS-PAGE) and followed by Coomassie Blue
staining of proteins in the gels (Fig. S7). Visible bands and the
same region in parallel gel lanes were harvested and proteins
present identified by mass spectrometry (MS). Stringent filtering of
the initial proteomic data resulted in a subset of 101 proteins that
either interacted with AIB1 (n=58, Table S1) or are present in
pY-protein complexes (n=56, Table S2), with 13 proteins
common to both.
The analytical approach emphasizes reliable identification of
proteins by correlating mass spectrometry ID with the apparent
molecular mass obtained from the SDS-PAGE (Fig. S7). This
approach mimics Western blotting without having to rely on the
availablility of antibodies, appropriate sensitivity, suitability for
Western blotting and specificity. Still, we used Western blotting of
some proteins identified by MS and show two examples in Fig. S8
(see below). To validate the mass spectrometry findings, separate
experiments with independent mass spectrometry analyses were
run. We found 48% of the proteins reported here in two and 16%
in three or more independent experiments. This compares
favorably with a recent HUPO study where only 7 of 27
laboratories identified all 20 proteins present at equimolar
concentrations in a test sample [41]. In our experiments, the
abundance of individual endogenous proteins captured in the
immunoprecipitates covers a wide range (see Fig. S7). Thus, we
expected that lower abundance proteins may drop below detection
in repeat experiments. A combination of bioinformatics and mass
spectrometry analysis was thus applied to meet this challenge as
also described elsewhere [42,43].
The Venn diagrams of proteins pulled down with anti-AIB1 or
anti-pY (Fig. 2)showthe distribution of proteins between E2-treated
and untreated, as well as wild-type MCF-7 versus MCF-7:5C cells
(A and B), or between E2-treated and untreated cells regardless of
cell type(C,top;a n dD ,top),orbetween MCF-7 andMCF-7:5Ccells
regardless of treatment (C, bottom;a n dD ,bottom). The number of
pY-complexed proteins identified was affected very little by E2
treatment (18 vs. 25 proteins) with 13 proteins in either treatment
group (Fig. 2D). In contrast, there was a significant, 4-fold higher
number of AIB1-interacting proteins in the E2-treatment group (8
vs. 33 proteins; p,0.05, chi-square test; Fig. 2C) with 17 proteins
not impacted in their interaction with AIB1. This suggests that
AIB1-mediated protein-protein interactions are more responsive to
E2 treatment, and new protein complexes are induced by E2
(Fig. 2A,C). In addition, the total number of proteins in complexes
with AIB1 that overlap between MCF-7 and MCF-7:5C cells was
not altered by the treatment, although the fraction of proteins per
cell line that overlap decreases by 1/2 with E2-treatment (31% to
16%; Fig. 2A). Finally, while pathways activated by E2 gave rise to
different sets of pY-containing protein complexes in both MCF-7
and MCF-7:5C cells, the percentage of proteins that overlap
between cell lines remain almost constant regardless of treatment
(4 vs. 5 in Fig. 2B).
Figure 3 shows the functional categories ascribed to the AIB1-
associated (top) and pY-complexed (bottom) proteins. Tables S1
and S2 identify the proteins in each of these categories, cell lines
(MCF-7 versus MCF-7:5C), and conditions (+/2 E2) under which
they were identified. Nearly half of the AIB1-interacting proteins
fall into four categories, i.e. cytoskeleton and structural proteins,
metabolism, transcription regulation, and signal transduction.
Most of the pY-complexed proteins fall into four major functional
categories: cytoskeleton and structural proteins, transcription
regulation, signal transduction, and protein transport and vesicle
trafficking. Thirteen proteins were found to be both AIB1-
interacting and pY-complexed in MCF-7 and MCF-7:5C cells
(Table S1).
Distinct profiles were observed for metabolism-related proteins
between AIB1- and pY-complexed proteins, where the AIB1
complexes contained eight different enzymes in contrast to only
one in the anti-pY group. This is consistent with studies
demonstrating that AIB1 plays a role in the control of basal
metabolic processes [44,45] that resulted in growth retardation and
reduced hormonal responses in AIB1 knock-out mice [46]. Quite
strikingly, all of these proteins were identified in E2 treated cells (e.g.
5-oxoprolinase in MCF-7:5C and fatty acid synthase in MCF-7
cells), whereas only three were identified in untreated as well as E2
treated cells. Seven AIB1-interacting proteins were detected in the
categories of transcriptional regulation and chromatin complex,
consistent with the role of AIB1 as a transcriptional coactivator.
Interestingly, several proteins were found with pY immunoprecip-
itation that wereunique to E2-treated MCF-7:5C cells, one of which
was FAK1 (PTK2; Table S2). FAK1 is known to complex with
EGFR as well as with an isoform of AIB1 and thus contribute to
cellular signaling in breast cancer cells [47]. The MS based
identification of FAK1 in the anti-pY immunoprecipitates was also
seen by Western blot (Fig. S8A).
AIB1-containing protein complexes in E2-treated MCF-
7:5C cells
We identified 18 proteins (CI .95%) that interact with AIB1 in
E2-treated but not in untreated MCF-7:5C cells, 10 of which are
also unique to MCF-7:5C cells (Table S1; Fig. 2A). These E2-
induced AIB1-interacting proteins in MCF-7:5C cells mainly
segregate in the category ‘‘transcriptional regulation’’ (6 of 18),
Estrogen-Induced Growth and Apoptosis
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apoptosis. For example, PRDM5, a PR domain and zinc-finger
transcriptional regulator is a putative tumor suppressor and has
been linked to cancer cell apoptosis [48]. TLE3, a transcriptional
corepressor that binds to a number of transcription factors [49],
can form a transcriptional repressor complex with RUNX3 [50], a
known tumor suppressor that has been shown to be involved in
apoptosis in gastric and colon cancer [51]. TLE3 has also been
associated with the development of anti-estrogen resistance [52].
The MS identification of the 83 kDa TLE3 in AIB1 immunopre-
cipitations (IP) by was also seen by Western blot analysis (Fig.
S8B). IASPP was identified in complex with AIB1 in both E2-
treated MCF-7 and MCF-7:5C cells, but not in untreated cells.
IASPP, a member of ASPP family of proteins, exerts anti-apoptosis
effects through modulation of p53 [53,54,55]. Interestingly
PRPF6, identified here as AIB1-interacting, is an U5 snRNP-
associated protein involved in pre-mRNA splicing and has been
shown to be a coactivator of the androgen receptor and mediates
its ligand-independent AF-1 activation [56]. TLE3, PRDM5 and
PRPF6 were all uniquely identified in E2-treated MCF-7:5C cells.
Potential pathways involved in E2-induced growth and
apoptosis
To increase the potential of identifying pathways participating
in E2-induced growth and apoptosis from the MS data sets, we not
only analyzed proteins identified from MS with high confidence
(CI $95%), but also took a global approach to include all proteins
identified at various CI levels (see http://pir.georgetown.edu/
iproxpress/coe2) by MS before filtering for pathway mapping with
the Ingenuity
TM and GeneGO
TM pathway tools [43]. We
hypothesized that if proteins identified at lower-level confidence
by MS are found in known pathways that are consistent with the
cellular phenotypes, they may provide valuable mechanistic
insights. Also, supporting this approach are data from a recent
study [57] with immunoprecipitation of nuclear extracts from
MCF-7 cells that identified 13 of the 15 proteins we had seen at CI
values in the lower range of 42–90%. The canonical pathway
mapping analyses of all identified proteins suggest that several
pathways are significantly represented both for proteins immuno-
precipitated with anti-AIB1 and for those with anti-pY, including
GPCRs, apoptosis, PI3K/AKT, and Wnt/b-catenin and Notch
signaling pathways (Fig. S1, S2, S3, S4):
GPCR and growth factor signaling. Figure S1 depicts the
GPCR-induced cell growth pathway, in which a number of
proteins were identified in both AIB1 and pY-associated
complexes. Ga(o) (GNAO2, IP-pY) and Rap1GAP (IP-AIB1)
(Table S3), for example were identified exclusively in E2-treated
MCF-7:5C cells. Ga(o) has been shown to directly bind to
Rap1GAP resulting in the inhibition of the Ras-MAPK
proliferation pathway [58]. In E2-treated MCF-7 cells, Ga(s)
(GAS, GNAS) and CALM1 were coimmunoprecipitated with
AIB1, while IP3R (ITPR3) was coimmunoprecipitated with AIB1
in both E2 treated MCF-7 and MCF-7:5C cells (Table S3). Each
Figure 2. Summary of proteins identified under different conditions. Venn diagrams of proteins identified from anti-AIB1 (A,C) or anti-pY IP
(B,D) experimental groups. (C,D) Proteins in combined AIB1-IP or pY-IP data sets. Individual proteins and subgroups are shown in Tables S1 & S2.
doi:10.1371/journal.pone.0020410.g002
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to MAPK pathway activation and cell proliferation.
GPCRs and growth factors (IGF-1 and EGF) act via
phosphorylation of the proapoptotic Bcl-2 family member BAD
to regulate mitochondrial-mediated apoptosis (Fig. S2). BAD has
been shown to be phosphorylated by Cdc2 (CDK1) at S128 [59]
and Cdc2 was identified by anti-pY immunoprecipitation in E2-
treated MCF-7:5C cells (Table S2). Also, two phosphatases, PP2B
(PPP3CB) and PP2C (WIP1; Table S3, Fig. S2), associated with
AIB1 only in MCF-7 cells. Both phosphatases can dephosphor-
ylate BAD and thus modulate apoptosis [60]. In addition, RSK1
and RSK2, identified only in E2-treated cells (Table S3, Fig. S2),
are also known to modulate cell survival [61,62].
Growth factors and cytokines can induce cellular growth and
proliferation through PI3K-AKT signaling. A number of proteins
complexed with AIB1 were identified in this pathway under
different conditions (Fig. S3 and Table S3). The non-receptor
tyrosine kinase TYK2 was detected in both MCF-7 and MCF-
7:5C cells with or without E2 treatment. Both PI3K catalytic
(p110) and regulatory (p85) subunits were pulled down only in E2-
treated, not in untreated MCF-7 cells (Fig. S3C). PI3K/p110 was
detected, additionally, in untreated but not treated MCF-7:5C
cells (Fig. S3B). Thus, PI3K/p110 was isolated only under
conditions that promoted proliferation in both cell lines. GSK3b,
identified in AIB1 immunoprecipitates in E2-treated MCF-7 cells
(Fig. S3C), can be activated by PI3K/AKT, and has also been
shown to be a regulator of Wnt signaling (see below). Finally,
BCL3, a member of the I-kappa-B family that regulates NFkB-
mediated transcription [63,64], was only identified in E2-treated
MCF-7 cells.
Wnt/b-catenin and Notch signaling. Our data indicate that
Wnt/b-catenin, and Notch signaling pathways participate in E2
responses in both MCF-7 and MCF-7:5C cells (Fig. S4). Several key
proteins in the pathway, such as Wnt ligands, cadherin, b-catenin,
casein kinases and GSK3b wereidentified in distinct AIB1- and pY-
containing complexes, amongst different cells and treatments (Fig.
S4A, B and C). For example, in MCF-7:5C cells, Frizzled-7 (FZD7)
and cadherin 22 (CDH22) were identified in pY-containing
complexes after E2 treatment, while b-catenin associated with
AIB1 regardless of E2 treatment (Table S3). In MCF-7 cells, the
Wnt ligand Wnt-7a, CK1d, and GSK3b were identified in AIB1
immunoprecipitates (Table S3). CK1d was recently reported to
modulate the transcriptional activity of ERa in an estrogen-
dependent manner and regulates ER-AIB1 interactions [65]. An
additional protein, d-catenin, or p120
ctn, a member of armadillo/b-
catenin superfamily [66], was identified in the AIB1 immuno-
precipitates of E2-treated MCF-7 cells (Table S1).
Our results suggest that multiple proteins found in AIB1
associated complexes, that function in Wnt signaling, also crosstalk
with Notch and growth factor-induced signaling in response to E2
treatment in breast cancer cells. TLE3 was detected only in E2-
treated MCF-7:5C cells, and Notch1, Notch3, and Numb-like
protein were identified only in E2-treated MCF-7 cells (Table S3).
TLE3, the mammalian homolog of Gro [67], is a global
corepressor mediating transcriptional repression targeted by a
number of signal pathways. As shown in Fig. S4D, TLE3 connects
the Notch and Wnt pathways [68,69]. In addition to the apoptosis
related proteins discussed above (TLE3, PRDM5, CDK1), DBC1
was isolated from anti-pY immunoprecipitates in E2 treated MCF-
7:5C cells (Table S2). Interestingly, DBC1 was recently reported to
increase p53 mediated apoptosis in breast cancer cells [70]. Taken
together, proteins from GPCR and PI3K/AKT-mediated growth
signaling pathways were more prevalent in E2-stimulated MCF-7
cells, whereas proteins related to apoptosis pathways were more
prevalent in E2-stimulated MCF-7:5C cells. The respective
connectivity of the pathways is depicted in Figure 4.
Global AIB1 interaction networks
To extract further information from these experimental data,
they were linked with an AIB1 interaction network generated from
published data [43]. A computational global AIB1 protein
interaction network can be constructed from 91 AIB1 interaction
partners (first neighbors) based on the literature published since
AIB1 was first described in 1997 [37]. These 91 proteins belong to
several major functional categories that include transcription, cell
communication, developmental processes and cell cycle regula-
tion. The initial network was expanded to secondary interaction
neighbors, based on protein-protein interaction data in the public
domain. At this level, the network is composed of 1150 proteins,
including 21 highly connected nodes that form major hubs (Fig. 5).
These hubs include p53, BRCA1, BCL2, ABL1, CDK2, CDK4,
EGFR, ER (=ESR1), p38, and MYC (Fig. 5 and S5). Closely
related subnetworks of AIB1 (=NCOA3) shown in Figure S5
(lower panel), contain four hub proteins: BRCA1, MYC, CDK2 and
PSME3. In the present study we identified 26 proteins that are
part of the global AIB1 interaction network and function in signal
transduction, transcriptional regulation, the cytoskeleton, and the
heat shock response.
Eighteen of the proteins experimentally associated with
tyrosine-phosphorylated protein complexes are also part of the
global AIB1-interaction network. Of these, seven were identified as
interacting with AIB1, including CALM1, ACTB, ACTG1,
TUBGCP2, MYH9, HSPA1B, and HSPA9. These proteins
correspond to interacting hubs, such as CDK4, MYC, PSME3
and CHUK. We conclude that these hubs may participate in the
differential cellular responses to E2.
Connection of E2 transcriptome and proteome effects
An interesting question is to what extent the proteomic pathway
mapping parallels mRNA expression profiling in MCF-7 and
MCF-7:5C cells. Baseline mRNA expression profiles of these cell
lines have been posted earlier (GSE10879; ncbi.nlm.nih.gov/). An
analysis of mRNA expression regulation after 48 hrs of E2
treatment of the cells was analyzed and published recently [71]. In
MCF-7 cells Bcl-2, a major anti-apoptosis gene, was found
upregulated by E2 treatment whereas no change of bcl-2 was seen
in MCF-7:5C cells. In our analysis Bcl-2 is one of the major hubs
in the AIB1 interaction networks (Fig. 5 and S5). On the other
hand, the pro-apototic Bcl-2 antagonists Bak, Bax and Bim
mRNAs were found upregulated 2- to 7-fold after E2 treatment of
MCF-7:5C cells whereas no mRNA expression change was seen in
the MCF-7 cells. Our analysis shows that upstream regulators of
the canonical intrinsic mitochondrial pathway such as RSKs, were
identified in the proteomics approach (Fig. 4 and S2).
The most differentially regulated mRNA after E2 treatment was
Gadd45beta that was found up-regulated 5-fold in MCF-7:5C cells
but down-regulated 5-fold in MCF-7 cells [71]. Gadd45beta was
described earlier as a hub of the MAP kinase signaling cascade and
Figure 3. Functional categories of anti-AIB1 (upper) and anti-pY immunoprecipitated proteins (lower) from MCF-7 and MCF-7:5C
breast cancer cells. Numbers in parenthesis are the number of proteins belonging to the respective category. Proteins profiled are those with CI
values $95% from mass spectrometry.
doi:10.1371/journal.pone.0020410.g003
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well as cell survival in apoptosis resistant cells [73]. We isolated
components of GPCR signaling in our proteomics analysis (Fig. 4
and Fig. S1) that can connect to these downstream effectors and
can thus serve as trigger mechanisms. Interestingly, GPR30
mRNA was found upregulated in MCF-7:5C cells after estradiol
treatment [40] and GPR30 was shown to rapidly transmit non-
genomic effects of E2 in breast cancer cells [74]. Overall, the
mRNA expression analyses and proteomics data show some
interesting convergences especially in apoptotic regulatory path-
ways which may be functionally relevant as initiators of estradiol–
induced apoptosis or cell survival.
Conclusions
The estrogen induced apoptotic response is most strongly
associated with early signaling changes in G-protein coupled
receptors, PI3 kinase, Wnt and Notch signaling and are integrated
here into a global AIB1 signaling network that controls
qualitatively distinct responses to estrogen.
Materials and Methods
The overall experimental design
We used combined proteomics and bioinformatics approaches
[43] to identify the E2 induced signaling pathways and networks
that are associated with AIB1 and/or tyrosine phosphorylated
proteins and that differentiate the MCF-7 from MCF-7:5C cells in
responses to E2 treatment (Fig. 1A). A single early time point after
E2 treatment (2 hrs) was examined to capture signaling events that
drive apoptosis or proliferation in these cells. Repeat independent
proteomic experiments for each of the 4 experimental conditions
and the two different immunoprecipitations were run.
Cell culture
MCF-7 (ATCC) human breast cancer cells and the MCF-7
variant MCF-7:5C [75] , which is a clonal variant of MCF-7
derived after longterm estrogen deprivation, were cultured in
RPMI-1640 without Phenol Red (Invitrogen) supplemented with
10% FBS, or in RPMI-1640 supplemented with 10% charcoal/
Figure 5. A global AIB1 interaction network showing the major hub proteins. Twenty-one hubs were identified using a cutoff of 20 node
degrees. The full names of the respective gene symbols are provided in Table S8. Detailed nodes in the network are shown in Fig. S5.
doi:10.1371/journal.pone.0020410.g005
Figure 4. Pathway overview map of proteins involved in E2-induced cell growth or apoptosis in MCF-7 versus MCF-7:5C breast
cancer cells. The thick grey line in the middle provides an arbitrary boundary between the pathways. Anti-AIB1 immunoprecipitated (AIB1-IPed) and
anti-pY-immunoprecipitated proteins (pY-IPed) are indicated by red or green circles respectively (keys at the bottom). The blue circled proteins are
AIB1-IPed proteins from MCF-7 (CALM1) or MCF-7:5C cells (b-catenin) under both E2-treated and untreated conditions; the purple circled one (ITPR3)
is an AIB1-IPed protein from both cells only under E2 treated condition, while the yellow circled one (TYK2) is an AIB1-IPed protein from both cells
under both E2 treated and untreated conditions. Proteins circled in grey are from known canonical pathways (e.g. ERK in cell growth or BAD in
apoptosis) but not identified here. Solid line arrows indicate direct interactions (e.g. CDK1 phosphorylates Rap1GAP) or translocations (e.g. catenins)
of proteins, while dashed arrows indicate indirect actions of proteins (e.g. AKT activate MEK through several steps). Hammer-ended lines indicate
inhibitory effects on the target. Detailled pathways are shown in Fig. S1, S2, S3, S4.
doi:10.1371/journal.pone.0020410.g004
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tively, as described previously [38]. MCF-7 or MCF-7:5C cells
deprived of steroid hormones for 2 days were plated at a density of
2,000 and 3,000 cells per well, respectively, in 96-well cell culture
plates. One day after plating, cells were treated with E2 (in
ethanol) or vehicle (ethanol). To monitor the portion of viable cells
after 6 days of growth, the CellTiter-Glo luminescent cell viability
assay (Promega) or WST1 colorimetric cell proliferation assay
(Roche) were used. Typical readings of baseline growth without E2
were 2.0610
5 RLU (CellTiter-Glo) or an OD450 of 0.5 (WST1).
Data are shown relative to the baseline.
Infection of MCF-7 and MCF-7:5C with lentiviral shRNA
expression vectors
Prior to infection, MCF-7 and MCF-7:5C cells were plated at a
density of 3610
5 cells on 10 cm tissue culture dishes. 24 hrs later,
cells were infected with lentiviral particles expressing control or
AIB1-targeting shRNAs (in pLKO.1). The AIB1(1) shRNA was
derived from an siRNA for AIB1 previously described [25], and
the AIB1(2) shRNA was from Sigma (TRCN0000019703). The
control shRNA used in the experiments is a scrambled sequence
described previously [76]. Briefly, 1 ml of lentivirus-containing
supernatant was added to 9 ml of growth medium and 8 ng/ml
polybrene, and then added to cells for 24 hrs. Medium containing
lentivirus was then replaced with growth medium without
lentivirus. After two days, cells were treated for 48 hours with
5 mg/ml puromycin for the selection of lentiviral shRNA
expression.
Western blot analysis, immunoprecipitation and protein
isolation
Western blot analyses were done as previously described [25],
using a monoclonal antibody for AIB1 (SRC3; clone 5E11, Cell
Signaling). For the mass spectrometry analysis, protein lysates
from cells treated for 2 hours with E2 or vehicle were subjected to
immunoprecipitation using gamma-bind G-Sepharose beads and
an anti-AIB1 monoclonal antibody (BD Biosciences) as described
[77] or an anti-phosphotyrosine monoclonal antibody (4G-10,
Millipore). The amount of protein input for immunoprecipitations
ranged between 7 mg and 14 mg for each of the experimental
conditions with bovine serum albumin used as the standard. It is
noteworthy that over a 24 hour period of E2 treatment of cells the
AIB1 protein expression levels varied less than 2-fold as illustrated
in Figure S6. The immunoprecipitated proteins were separated by
denaturing SDS-PAGE on 4–12% Nu-PAGE gels (Invitrogen).
After electrophoresis, gels were stained with Coomassie blue
overnight and washed with ddH2O overnight to remove
background staining. Stained gels were imaged using a color
scanner and visible bands were cut from the gels. The
corresponding segments of lanes from the different treatments
were also cut for analyses and served as controls. Figure S7 shows
a representative set of stained gels with an overlay of the grid of
segments harvested for the mass spectrometry analyses.
Mass spectrometry analysis
SDS-PAGE gel slices were subjected to tryptic digest and
followed by MS and MS/MS on an ABI MALDI-TOF-TOF.
Proteins in the MS or MS/MS analysis were identified based on
searches of the Swiss-Prot database using the search engine
Mascot 2.0. The Swiss-Prot database searched was based on its 9/
24/2007 release (287,050 sequences). The database search
parameters used were: 1) enzyme specificity considered, trypsin;
2) number of missed cleavages permitted, 1; 3) fixed modifica-
tion(s), carbamidomethyl (C); 4) variable modification(s), oxidation
(M); 5) mass tolerance for precursor ions, 75ppm; and 6) mass
tolerance for fragment ions, 0.3 Da. Trypsin autolysis peaks were
excluded from the peak list. GPS Explorer (Version 3.0) with
default parameter setting was used to generate the peak list from
raw data which were submitted to database searches using Mascot.
The confidence interval (CI) for the peptide identification was
calculated by GPS Explorer. A CI of $95% (or expectation value
#0.05) was used as a cut off for the high CI proteins.
Bioinformatics Analysis
Protein data filtering. Proteins identified from mass
spectrometry were subjected to extensive bioinformatics analysis,
including protein data filtering, functional profiling and pathway
mapping as described previously [78]. Protein identities from
different experimental groups were assigned levels of identification
confidence based on statistical processing by GPS Explorer
TM of
the MASCOT search results. It is commonly known that false
negative identification is generated because low-scored proteins
may result from factors such as database size, protein abundance
and the type of mass spectrometry instrumentation. Therefore, in
addition to analyzing the proteomic data based on the prioritized
list of proteins with high Confidence Interval (CI; Tables S1, S2),
we also used a global approach for pathway mapping on proteins
identified at all confidence levels. We provide the identity, CI and
spectra of those proteins as well as the reference to the respective
pathway figures in Table S3.
We used the following criteria to filter the protein lists. (i)
Proteins with MS confidence interval (CI) values smaller than 95%
were removed to reduce false-positive results; (ii) Proteins
described to be non-specific interactors e.g. HSPA5 and
Desmoplakin [79] were removed; (iii) High abundant, non-specific
proteins e.g. keratins were removed; (iv) Proteins migrating at an
apparent mass in the SDS-PAGE that was different from the
calculated mass or the experimentally described mass or the
predicted mass were removed. A representative set of Coomassie
stained gels after immunoprecipitations is shown in Fig. S7 to
illustrate this latter consideration.
Protein annotation, profiling and pathway analysis. The
iProXpress bioinformatics system (http://pir.georgetown.edu/
iproxpress) was used for protein annotation, function and
pathway profiling of the proteomics data. The experimental
group(s) in which the proteins were identified was annotated for all
proteins and integrated into the iProXpress system for direct
functional comparison between selected groups, such as cell types,
E2 treatment, and experimental repeats. The procedure of using
iProXpress system has been described recently [43,78]. The data
sets are accessible at http://pir.georgetown.edu/iproxpress/coe2/
. Pathway mapping and network visualization are assisted with
Ingenuity Pathways Analysis (IPA) (www.ingenuity.com) and
GeneGO MetaCore (www.GeneGO.com) software tools.
Data mining for known AIB1 interactors. The global
AIB1 interaction network refers to a network of genes or proteins
that directly or indirectly interact or are functionally associated
with AIB1 regardless of cell/tissue types or species in which the
interaction occurs. The network is was computationally generated
based on two sources of data, i.e. the published literature
(PubMed) and protein-protein interactions (PPI) available from
public databases. A list of AIB1 synonyms included as query terms
‘‘AIB1 OR AIB-1 OR NCOA3 OR NCOA-3 OR SRC3 OR
SRC-3 OR TRAM1 OR ACTR OR pCIP’’ to search PubMed
and retrieved a total of about 650 papers related to AIB1. Of these
papers about 250 papers that contain AIB1 interaction or
functional association information were curated, and a total of
Estrogen-Induced Growth and Apoptosis
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types in the literature included physical interactions, such as
‘‘binding’’, ‘‘complex’’, ‘‘interact’’, ‘‘phosphorylation’’, etc., and functional
associations, such as ‘‘activation’’, ‘‘correlated expression’’, ‘‘lead to
degradation’’, ‘‘modulate’’, ‘‘promoter binding’’, ‘‘suppression’’, etc. These
interacting proteins/genes reported for human as well as other
species from mouse to Xenopus, were mapped to corresponding
human orthologs based on UniProtKB database.
The protein/protein interaction (PPI) data annotated in
bioinformatics databases were obtained from IntAct database
[80], which contains high throughput PPI data from Y2H and IP
in addition to literature data. The AIB1 interaction network was
constructed based on the binary interactions of the curated 91
AIB1-interacting proteins and those from the PPI database. The
network was clustered and filtered, and major hubs were selected
using a cutoff of a node degree of 20. Cytoscape open source
software was used to display the network for visual examinations.
Supporting Information
Figure S1 Proteins identified in GPCR signaling path-
ways. Canonical cell growth pathways initiated by GCPR
signaling are depicted based on the MetaCore pathway tool of
GeneGO. The AIB1- and pY-IPed proteins identified from the
study were mapped to the pathway using MetaCore, which were
manually re-annotated in the red-lined white boxes with black
arrows pointing to the specific protein depictions. The corre-
sponding experimental conditions under which the proteins were
identified are indicated at the bottom. Proteins were AIB1-IPed
under conditions indicated as A–D, or pY-IPed indicated by ‘‘p’’.
(TIF)
Figure S2 Proteins identified in apoptosis pathways.
The canonical intrinsic mitochondrial apoptosis pathway is
depicted based the MetaCore pathway tool of GeneGO. Similar
to Fig. S3, the anti-AIB1- and pY-IPed proteins identified from the
study were mapped to the pathway and were manually re-
annotated with red-lined white boxes with the specific protein
identified here.
(TIF)
Figure S3 Proteins identified in the PI3K/AKT path-
way. The canonical PI3K/AKT pathway is depicted based on
the Ingenuity pathway tool. AIB1-IPed proteins that were mapped
to the canonical pathway are shown as orange-colored shapes in
four panels, each representing the same PI3K/AKT pathway with
different mapped proteins that were identified from untreated
MCF-7 (A) or MCF-7:5C (B) and E2-treated MCF-7 (C) or MCF-
7:5C (D) cells. Some proteins in the pathway were manually re-
annotated with green-colored box to indicate the specific protein
forms identified in this study that correspond to the protein classes
represented in the canonical pathway, e.g. JAK refers to the non-
receptor type tyrosine kinases, such as TYK2 here.
(TIF)
Figure S4 Proteins identified in the Wnt/b-catenin
pathway. The canonical Wnt/b-catenin pathway is depicted
based on the Ingenuity pathway tool. AIB1-IPed proteins that can
be mapped to the canonical pathway are shown as orange-colored
shapes in four panels, each representing the same Wnt/b-catenin
pathway with different mapped proteins that were identified from
untreated MCF-7 (A) or MCF-7:5C (B) and E2-treated MCF-7 (C)
or MCF-7:5C (D) cells. Some proteins in the pathway were
manually re-annotated with green-colored box to indicate the
specific protein forms identified in the experiment that correspond
to the classes represented in the canonical pathway, e.g. Wnt refers
to class of Wnt ligands, such as Wnt-4 and Wnt-7a. Some proteins
manually labeled with a ‘‘P’’ in red indicate that they were
identified as pY-IPed.
(TIF)
Figure S5 AIB1 interaction network. A global AIB1
interaction network (upper) and the selected sub-networks (lower)
are shown. The overall topology of the network is displayed with
Spring-embedded layout using Cytoscape network visualization
software before network clustering (image can be zoomed in to
view individual node). Proteins that are identified with high
confidence in this study are colored as green (AIB1-IPed), yellow
(pY-IPed) or dark brown (both AIB1- and pY-IPed) nodes. Hub
proteins that are subsequently clustered with AIB1 in several
subnetworks are indicated with arrows (upper). Individual nodes in
AIB1-clustered subnetworks are shown in the lower panel, with
major functional categories labeled for the hub proteins.
(TIF)
Figure S6 Western blot analysis for AIB1. Cells treated
with E2 for different times were harvested and Western blot
analysis for AIB1 was performed as described in Materials and
Methods.
(TIF)
Figure S7 Coomassie stained protein gels after anti-
AIB1 or -pY immunoprecipitation (IP). MCF-7 and MCF-
7:5C cells were treated or not with E2for 2 hours, and proteins were
extracted for IP. The immunoprecipitated proteins were separated
by 4–12% Nu-PAGE, stained, washed with ddH20 and imaged
using a color scanner. The images were magnified and analyzed
visuallyonascreen.Afteridentification,bandswerecutfromthegels
and greatcarewastaken to isolatethesamesegmentofall lanesfrom
the different treatments for a parallel MS analysis. Representative
stained gels with the segments to be cut for analysis are indicated.
Slices numbered 1–10 or 1–13 were cut from the gels for each
segment that showed at least one distinctly regulated protein.
Molecular masses of marker proteins are indicated (10–250 kDa).
(TIF)
Figure S8 Western blot analysis confirms that FAK1 and
TLE3 are immunoprecipitated from E2 treated
MCF7:5C cells. MCF-7:5C cells were treated or not with E2
for 2 hours, and proteins were extracted for IP/Western analysis
A) Tyrosine-phosphorylated endogenous proteins were immuno-
precipitated with anti-phosphotyrosine monoclonal antibody (4G-
10, Millipore) and the immunoprecipitate was resolved on SDS-
PAGE followed by Western analysis. The input is 5% of the
amount of total cell lysates for IP. FAK1 was detected on the blot
with an anti-FAK1 antibody (A-17, Santa Cruz). B) AIB1
interacting proteins were immunoprecipitated using an anti-
AIB1 monoclonal antibody (BD Biosciences). The input is 5% of
the amount of total cell lysates for IP. TLE3 was detected on the
blot with a TLE3 antibody (Abcam).
(TIF)
Table S1 AIB1-interacting proteins with a CI value of
$95%. AIB1-interacting proteins (n=58) isolated from MCF-7
and MCF-7:5C cells identified by MALDI-MS/MS with a CI
value of $95% are listed and assigned with functional categories.
The number of peptides identified and % coverage are in Table
S4. Various experimental groups in which AIB1-interacting
proteins were identified, are shown in the right side columns
(with vertical column names), and the number of total proteins in
each group is given in parenthesis. Proteins are arranged by their
functional categories (see Fig. 3) and the number of proteins in
each experimental group of a given category is also indicated in
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shows AIB1-interacting proteins in this study that are also
identified as part of the AIB1 protein interaction (int.) network.
‘‘X’’ indicates the presence of a given protein in a given
experimental group or in the AIB1 interaction network. Asterisks
by the protein accession indicate AIB1-interacting proteins that
are also identified in pY complexes (see Table S2).
(DOC)
Table S2 Phosphotyrosine complexed proteins with a
CI value of $95%. Proteins pulled down with anti-pY in MCF-7
and MCF-7:5C cells identified from MALDI-MS/MS with a CI
value of $95% are listed and assigned with functional categories.
The number of peptides identified and % coverage are in Table S5.
Various experimental groups in which tyrosine-phosphorylated
proteins are identified are shown in the right columns (with vertical
column names), and the number of proteins in each group is given
in parenthesis. Proteins are arranged by their functional categories
(see Fig. 3) and the number of proteins in each experimental group
of a given category is also indicated in the same row of the category.
‘‘X’’ indicates the presence of a given protein in a given
experimental group or in the AIB1 interaction network. Asterisks
by the protein accession indicate IP-pY complexes that are also
identified as AIB1-interacting (see Table S1).
(DOC)
Table S3 Pathway mapping of proteins identified with a
CI,95%. Proteins are listed alphabetically based on the ‘‘gene
name’’ column for anti-AIB1 or anti-pY immunoprecipitated
proteins. In the ‘‘Experiment’’ column A to D indicate: A, MCF-7
cells, no E2; B, MCF-7:5C cells, no E2; C, MCF-7 cells, +E2; and
D, MCF-7:5C cells, +E2. The ‘‘Spec’’ column references the
corresponding mass spectrum for single peptide MS/MS identi-
fication in the section ‘‘Single peptide spectral data’’ appended at
the end of this table. The ‘‘Figures’’ column indicates in which
figure(s) the proteins are depicted, except for a few only discussed
in the main text (text). In the spectral data section, the underlined C
and M in ‘‘peptide sequences’’ column represent fixed (carbami-
domethyl) and variable (oxidation) modifications, respectively.
*MALDI-TOF-MS generates peptides containing only one
charge, and the precursor m/z is thus equal to the precursor
mass. NA, not available.
(DOC)
Table S4 AIB1-complexed proteins identified by
MALDI-TOF-TOF. Proteins were identified based on single
MS (MS) or tandem MS (MS/MS) using the search engine Mascot
2.0 from the Swiss-Prot database. Note that the same proteins
could be identified under different experimental (‘‘Exp.’’) condi-
tions: A, MCF-7 cells, no E2; B, MCF-7:5C cell, no E2; C, MCF-7
cell, +E2; D, MCF-7:5C cell, +E2. For proteins identified from
single peptide MS/MS, spectral data (Spec.) are referenced using
the labels (A1–A30) to correspond to those shown in Table S6. All
spectra for single peptides shown here are manually inspected,
including the one that shows CI of 93% but with good ion
fragments. *The % coverage for single peptide MS/MS was only
stated if the respective peptide covered $1% of the protein. The
spectra and sequences are in Table S6.
(DOC)
Table S5 pY-complexed proteins identified by MALDI-
TOF-TOF. Proteins were identified based on single MS (MS) or
tandem MS (MS/MS) using the search engine Mascot 2.0 from
the Swiss-Prot database. Note that the same proteins could be
identified under different experimental (‘‘Exp.’’) conditions: A,
MCF-7 cells, no E2; B, MCF-7:5C cell, no E2; C, MCF-7 cell,
+E2; D, MCF-7:5C cell, +E2. Proteins that were identified more
than once from experimental repeats under the same conditions
are labeled with * in the ‘‘Exp’’ column. For proteins identified
from single peptide MS/MS, spectral data (Spec.) are referenced
using the labels (Y1–Y38) to correspond to those shown in Table
S7. All spectra for single peptides shown here were manually
inspected, including those that show 90%# CI #95% but with
good ion fragments. *The % coverage for single peptide MS/MS
was only stated if the respective peptide covered $1% of the
protein. The spectra and sequences are in Table S7.
(DOC)
Table S6 MS/MS spectra for single peptide identified
AIB1-complexed proteins. The ‘‘No.’’ column labels the
spectra sequentially as referenced in Table S4. The ‘‘Exp.’’
column indicates the experimental conditions under which the
respective protein was identified: A, MCF-7 cells, no E2; B, MCF-
7:5C cell, no E2; C, MCF-7 cell, +E2; D, MCF-7:5C cell, +E2.
The underlined C and M in peptide sequences represent fixed
(carbamidomethyl) and variable (oxidation) modifications, respec-
tively. *MALDI-TOF-MS generates peptides containing only one
charge and the precursor m/z (not shown) is thus equal to the
precursor mass.
(DOC)
Table S7 MS/MS spectra for single peptide identified
pY-complexed proteins. The ‘‘No.’’ column labels the spectra
sequentially as referenced in Table S5. The ‘‘Exp.’’ column
indicates the experimental conditions under which the protein was
identified: A, MCF-7 cells, no E2; B, MCF-7:5C cell, no E2; C,
MCF-7 cell, +E2; D, MCF-7:5C cell, +E2. The underlined C and
M in peptide sequences represent fixed (carbamidomethyl) and
variable (oxidation) modifications, respectively. *MALDI-TOF-
MS generates peptides containing only one charge and the
precursor m/z (not shown) is thus equal to the precursor mass.
(DOC)
Table S8 List of acronyms used.
(DOC)
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